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Abstract
Objective—We examined the neuropsychological functioning of youth enrolled in the NIMH 
funded trial, Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS). We 
compared the baseline neuropsychological functioning of youth with schizophrenia (SZ, n = 79) to 
those with schizoaffective disorder (SA, n = 40), and examined the relationship of different 
variables of illness severity and adaptive behavior to neuropsychological functioning.
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Method—Participants ranged in age from 8 to 19 years. Diagnostic status was confirmed via 
structured interview over multiple time points. Domains of neuropsychological functioning 
included fine-motor, attention, working memory, problem-solving efficiency, inhibitory control, 
and social cognition. Other variables included intelligence (IQ), academic achievement skills, 
adaptive behavior, and different measures of illness severity.
Results—The two groups did not differ on IQ or on any of the neuropsychological domains. The 
SZ group performed significantly lower in spelling. A high proportion of individuals in both 
groups reflected significant intellectual and academic achievement skill deficits. Significant 
correlations were found between the neurocognitive domains and both illness severity and 
adaptive behavior variables.
Conclusions—There were few differences between the SZ and SA groups on IQ, achievement, 
or neuropsychological functioning; however, both groups showed significantly high rates of 
deficits in IQ and basic academic skills. Correlations of the neurocognitive functions with illness 
severity and adaptive behavior were small to moderate in magnitude. These findings continue to 
implicate the importance of neurocognitive functioning as a key area of vulnerability in the study 
of youth with schizophrenia spectrum disorders.
Keywords
early-onset schizophrenia; childhood schizophrenia; schizoaffective disorder in childhood; 
neurocognition in schizophrenia
Although evidence has emerged over the past 15 to 20 years related to the neurocognitive 
features of early-onset schizophrenia spectrum disorders,1–7 debate continues as to whether 
schizophrenia (SZ) and schizoaffective (SA) disorder are continuous or distinct 
conditions.8–10 Among the many issues that represent points of controversy is the level and 
pattern of neurocognitive deficit associated with each disorder.11 Mixed findings are 
reported in the limited research that has been conducted with adult samples,12 and the issue 
has not been carefully examined in children and adolescents. The Treatment of Early Onset 
Schizophrenia Spectrum (TEOSS) study provides an opportunity to compare the level and 
pattern of neurocognitive functioning in a large sample of youth with onset of SZ or SA 
prior to 18 years of age.
Studies of adults suggest that the cognitive and functional outcomes of SA are intermediate 
between those with SZ (who have lower functioning) and those with depression or bipolar 
disorder alone (who have higher functioning).13–16 Individuals with the bipolar subtype of 
SA appear to have better outcomes than individuals with the depressive subtype. In the few 
studies examining neurocognition, memory impairments are reported to be greater in SZ 
than in SA groups.16,17 Apart from emerging evidence suggesting that adults with SA 
perform better on measures of social cognition, there are few, if any, additional reliable 
differences in cognitive functioning between these diagnostic groups.18,19
In the available studies of youth with early-onset schizophrenia spectrum disorders (EOSS), 
children and adolescents have evidenced generalized neurocognitive deficits compared with 
healthy community controls.4–6,20 However, when youth with EOSS are compared with 
groups with other psychotic illnesses (e.g., bipolar disorder, psychosis NOS), no significant 
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group differences have been documented.21 Further, there is no published research 
comparing the level and pattern of neurocognitive functioning of youths with SZ or SA.
To this end, we examine the baseline neurocognitive characteristics of youths with SZ or SA 
participating in the TEOSS study. The analyses complement a prior publication on this same 
sample that compared the clinical and functional characteristics of children and adolescents 
with SZ or SA.21 In that paper, we reported similar levels of clinical symptoms and 
functioning across domains between the two diagnostic groups.17 Taken together with the 
limited adult literature, we hypothesized that group comparisons on neurocognitive 
functioning would yield more similarities than differences.
METHOD
Participants
Participants included 119 children and adolescents ranging in age from 8.1 to 19.3 years 
(mean = 14.25 years, SD = 2.41). The sample was approximately two-thirds male, 61.4% 
white and 88.3% right handed, and fell within the low-middle socioeconomic strata as 
determined by family income. Approrximately 45% of the sample was receiving special 
education services at the time of enrollment. Approximately 53% had a previous psychiatric 
hospitalization, and 56% had previously received pharmacological treatment for mood 
and/or behavioral difficulties. At baseline, approximately 68% were receiving some type of 
psychiatric medication; however, none were receiving any anti-psychotic pharmacological 
agents for their schizophrenia spectrum difficulties. Only 11 of the participants had engaged 
in illicit substance usage. Inclusion criteria included meeting DSM-IV22 criteria for 
schizophrenia, schizophreniform disorder, or schizoaffective disorder, via the Structured 
Clinical Interview for DSM-IV Childhood Disorders (KID-SCID),23 and a score of at least 
moderate on one or more of the positive psychotic symptoms of the Positive and Negative 
Syndrome Scale (PANSS). Interrater reliability within and between sites was maintained at 
≥0.80.
The KID-SCID was selected because of its greater sensitivity to psychotic symptomatology 
and clear diagnostic algorithms for determining SA versus SZ. Furthermore, all diagnoses 
were reassessed upon termination of study participations using the KID-SCID in an effort to 
examine severity and duration of mood symptoms relative to psychotic symptoms. Early 
diagnoses were found to be stable, with only one participant’s diagnosis changing from SZ 
at baseline to SA at study endpoint. All clinicians were fully trained general psychiatrists, 
and many had participated in adult studies in which psychotic symptoms and diagnoses were 
evaluated. The TEOSS protocol was approved by the Institutional Review Boards at all four 
participating sites. A more complete description of TEOSS methods is published 
elsewhere.24
Measures
The battery of tasks assessed targeted neurocognitive domains: fine-motor speed (Manual 
Finger Tapping Test,25 Grooved Pegboard26) attention and inhibitory control (VIGIL 
Continuous Performance Test27), working memory (Hopkins Verbal Learning Test,28 Wide 
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Range Assessment of Memory and Learning Visual Learning Subtest,29 Visuospatial 
Working Memory Test,30 Woodcock-Johnson-III Numbers Reversed Subtest31), problem-
solving efficiency (Controlled Oral Word Association-Semantic,32 Ruff Figural Fluency,33 
Wisconsin Card Sorting Test-6434), and social cognition (Eyes Test35). Psychoeducational 
tasks measured intelligence (Wechsler Abbreviated Scales of Intelligence36) and basic 
academic achievement skills (Wide Range Achievement Test–337). There was coordination 
with some measurement in the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) study that was examining similar questions in older adolescents and adults.38
Measures were blocked and the blocks counterbalanced to control for order effects. The 
blocks were constructed such that at least one measure represented each of the 
neurocognitive domains so that we could obtain information on a specific domain in the 
event that a participant was unable to continue for any reason. In addition, a number of 
measures were used to address symptom severity and functional status including the Positive 
and Negative Symptom Scale (PANSS),39 Clinical Global Impressions Scale (CGI),40 Brief 
Psychiatric Rating Scale for Children (BPRS-C),41 Child Behavior Checklist (CBCL),42 and 
Vineland Adaptive Behavior Scale (VABS).43
Data Analyses
Preliminary data analyses compared the SZ and the SA groups on demographic and illness-
related variables. Any variables found to be significantly different between the groups were 
considered as covariates in subsequent analyses.
Using univariate analyses of variance, we examined group differences on the 
psychoeducational measures (IQ, achievement). For any significant group differences, effect 
sizes were calculated using Cohen’s d statistic. In addition, given that the WASI and 
WRAT-3 are well normed, we examined the percentage of participants falling ≥1 standard 
deviation (SD) below each of these tests’ means as another clinical index of functioning.
For the neurocognitive tasks we created sample-based z-scores using the entire sample of 
EOSS cases.44 All z-scores were scaled such that higher scores reflected a better 
performance with respect to the overall sample mean. Using these z-scores, we then created 
neurocognitive domain scores and calculated alpha coefficients for each domain: Fine-
Motor (Fingertapping Dominant + Fingertapping Nondominant + Grooved Pegboard 
Dominant + Grooved Pegboard Nondominant), Attention (Visual CPT Omission Errors + 
Auditory CPT Omission Errors), Working Memory (HVLT Total + WRAML Total + 
Visual-Spatial 5′ Delay + Numbers Reversed), Problem Solving Efficiency (WCST 
Categories + WCST Perseverations + COWA Semantic Fluency + Ruff Unique Designs), 
Inhibitory Control (Visual CPT Commission Errors + Auditory CPT Commission Errors), 
and Social Cognition (Eyes Test Total Correct). Using General Linear Modeling, we 
conducted a series of univariate analyses across the two groups on the neurocognitive 
domains and their associated tasks controlling for chronological age (because several of the 
tests were administered out of normative range) and any other demographic variables that 
may have been different between the groups. For any significant group differences, effect 
sizes were calculated using Cohen’s d statistic.
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Finally, we conducted Pearson correlations, partial-ling out chronological age, between the 
neurocognitive domains and symptom severity as defined by scores from the PANSS, 
BPRS-C, CGI, and CBCL, and selected illness-related variables (illness duration, age of 
onset). A similar analysis was conducted between the neurocognitive domains and the 
VABS.
RESULTS
Preliminary Group Comparisons
Of the 119 participants in this study, 89.9% of the participants were able to complete some 
of the tests in the neuropsychological assessment battery. Given our blocking strategy, 
completion rates ranged from 80.0% for the Social Cognition Domain to 89.0% for the 
Problem Solving Efficiency Domain. Eleven participants were unable or unwilling to 
complete any of the neuropsychological tasks at baseline. When these individuals were 
compared with the rest of the sample, no differences were noted for age, gender, race, or 
family income. With respect to illness-related variables, these groups did not differ on the 
number of previous psychiatric hospitalizations, prior medication use, age at first psychosis, 
duration of illness, CGI, BPRS-C Total Summary Score, PANSS Positive Symptoms, 
PANSS Negative Symptoms, or PANSS Total Summary.
Descriptive information characterizing the sample is provided in Table 1. The two 
diagnostic groups did not differ on chronological age, gender, race, or handedness. The SA 
group had significantly higher family income than the SZ group, t (109) = −2.05, p < .04. 
With respect to illness-related variables, the two groups did not differ on the number of 
previous psychiatric hospitalizations, prior medication use, age at first psychosis, duration of 
illness, special education services, PANSS Summary score, PANSS Positive Symptoms 
Scale, BPRS-C, or the CGI. The groups differed on the PANSS Negative Symptoms Scale, t 
(115) = 2.30, p < .02, with the SZ group having more negative symptoms.
Intellectual and Academic Skills of Youth with SZ versus SA
The overall intellectual functioning for the sample fell within the low-average to average 
range, with the verbal and performance IQs being evenly developed within that range (Table 
2). Reading and spelling skills fell within a comparable range of functioning, although 
arithmetic skills were nearly 1 SD below the normative mean.
The two groups did not differ in terms of their Verbal IQ, Performance IQ, Full Scale IQ, or 
arithmetic skills (Table 2); however, group differences approached significance on reading, 
F (1, 97) = 2.71, p < .10, and the groups were significantly different on spelling, F (1, 96) = 
3.92, p < .05. For both reading and spelling, the SA group performed at a higher level.
Percentage of Participants Falling ≥1 SD Below the Mean—Given the relatively 
lower IQ and achievement scores, the possibility that a large number of participants were 
performing at a significantly lower level of functioning was examined. In this regard, we 
determined the percentage of participants who fell ≥1 SD below the normative mean (i.e., 
standard score ≤85). For IQ, the percentage of participants who fell ≥1 SD below the mean 
ranged from about 32% (Performance IQ) to nearly 39% (Full Scale IQ). For academic 
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achievement, these percentages ranged from approximately 22% (WRAT-3 Reading) to 
approximately 51% (WRAT-3 Arithmetic). Taken together, these percentages reveal that a 
high proportion of the entire sample is functioning below average on indices of IQ and 
academic achievement skills. Despite the relatively large number of individuals that met this 
criterion in the overall sample, there were no significant differences between the percentages 
represented in each of the diagnostic groups.
Neurocognitive Functioning of SZ versus SA
Once sample-specific z-scores for each of the neurocognitive tests and their associated 
domain were created, alpha coefficients for these domains were deemed to be satisfactory 
(ranging from 0.71 on Inhibitory Control to 0.85 for Fine-Motor Speed). In addition, all of 
the tasks had good floors and ceilings with this sample, so no range restrictions were noted. 
After controlling for age, there were no significant differences between the groups across the 
six neurocognitive domains or on any of the specific neurocognitive measures (Table 3). 
The results were relatively unchanged when both age and socioeconomic status were 
included as covariates.
Relationship Between Neurocognitive Functions, Symptom Severity, and Adaptive 
Behavior
Symptom Severity—After controlling for age, there were no significant correlations 
between the neurocognitive domains and the PANSS Positive, PANSS Negative, PANSS 
Summary, BPRS-C Total Summary, and the CBCL summary scales. Of the neurocognitive 
domains, only Full Scale IQ was significantly, but weakly, correlated with age of onset (r = 
−0.28) and duration of illness (r = 0.30). This implies that higher IQ was modestly 
associated with a younger age of onset and a longer duration of illness. The latter variable of 
illness duration may be an artifact of being diagnosed at a younger age and, indeed, these 
variables were highly correlated (r = −0.68); however, this finding does not support the 
common notion that diagnosis at a younger age portends a more severe form of the disorder
—at least not from a cognitive perspective. In fact, when we examined these relationships, 
there was little evidence for a significant association between clinician ratings of illness 
severity and age of onset (r = 0.14), or clinician ratings of illness severity and illness 
duration (r = −0.04). This conceptualization is supported, in part, by the significant negative 
relationship between higher IQ being associated with better clinician ratings of illness 
severity on the CGI (r = −0.27). This relationship could reflect an interesting artifact such 
that higher IQ (e.g., a highly verbal individual) may influence clinician ratings of illness 
severity in a positive direction. The most consistent pattern of correlations was observed for 
the CGI ratings at baseline, with correlations ranging from −0.24 (Attention) to −0.37 
(Problem Solving Efficiency). For the CGI, better ratings of global impairment were 
associated with better attention and problem-solving capabilities.
Adaptive Behavior—Consistent with the adult literature, a more robust pattern of 
correlations was noted between the neurocognitive domains and adaptive behavior, as 
displayed in Table 4. The VABS Communication Skills, Daily Living Skills, and Social 
Skills were each significantly correlated with IQ and four or more of the seven 
neurocognitive domains. Correlations ranged from small (r = 0.21, p < .05, between Social 
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Cognition and VABS Communication) to moderate (r = 0.45, p < .001, between Working 
Memory and VABS Communication). Attention, Working Memory, and Problem Solving 
Efficiency had the most robust associations with adaptive behaviors. All of the correlations 
were in the expected direction (i.e., higher neurocognitive domain scores were associated 
with higher adaptive behavior skills).
Similar relationships were observed between nearly all of the neurocognitive domains and 
the adaptive behavior composite (Table 4). For the adaptive behavior composite, 
correlations ranged from small (r = 0.23, p < .01) for Social Cognition to moderate (r = 0.44, 
p < .001) for Working Memory. Inhibitory Control did not significantly correlate with the 
Vineland Adaptive Behavior Composite, but it approached significance (r = 0.19, p < .07) in 
the expected direction.
DISCUSSION
We did not find significant differences between youth with SZ and those with SA disorder 
on any of the neuropsychological variables. The only significant group difference was 
obtained within the academic skill domain, in which the SZ group performed significantly 
lower on a task of single word spelling. These results are consistent with our earlier 
findings17 that indicated few clinical differences between these groups. Although some 
studies of adults suggest that individuals with SZ have greater cognitive impairment than 
those with SA,45 the available evidence also suggests a lack of differentiation between these 
two disorders in adults.18,19,46 These findings are inconsistent with the theory that SA 
disorder might represent the juxtaposition of two different illnesses, or a more severe variant 
of schizophrenia, as both of these models would instead predict the greatest cumulative 
deficits for SA versus “pure” SZ cases.
A substantial proportion of participants across both diagnostic groups demonstrated 
clinically significant intellectual impairment and academic delays. Approximately one-third 
of the sample was ≥1 SD below the normative mean in their Verbal, Performance, or Full 
Scale IQ scores. The greatest academic deficits were in arithmetic, in which more than half 
of the entire sample was ≥1 SD below the mean. Nearly one-quarter of the sample also was 
below average in reading and spelling. Although neurologically based explanations (e.g., 
right hemisphere involvement, efficiency of white matter tracts) and/or neurodevelopmental 
models (e.g., onset is preceded by a more vulnerable premorbid period marked by lower 
IQ47) could be invoked to explain why math skills were significantly lower for this group 
when compared with normative expectations, a more parsimonious explanation is that 
school-related learning experiences are less available to these children because of the 
psychological limitations imposed by the illness. Further, the combination of cognitive 
deficiencies and serious psychiatric difficulties may result in limited cognitive resources 
available for other adaptive functions, such as learning hierarchical information found in 
mathematics or the acquisition and developmental progression of reading and spelling skills. 
Taken together, these deficits will place many children with schizophrenia spectrum 
disorders at risk for school failure.
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The CGI ratings of illness severity at baseline provided the most extensive correlations with 
neurocognitive functioning, with less symptom severity being related to higher 
neurocognitive performance. Similarly, we found the social, communication, and daily 
living adaptive behavior skills, as well as overall adaptive behavior functioning, to be 
significantly correlated with nearly all of the neuropsychological domains. These significant 
relationships are not surprising, and reflect that more severely ill youth typically have 
greater impairments in multiple domains. The magnitude of these associations is moderate, 
and becomes even more impressive when considering that the correlations are not inflated 
by shared method variance.48 Similar associations have been reported in the adult 
literature.49,50 These results strengthen the notion that at least some of the burden of SZ-
related disorders may be due to impaired neurocognitive functioning.
One curious finding relates to the significant relationship between Full Scale IQ and age of 
onset of the disorder, where higher IQ was associated with a younger age of onset. This 
finding does not support the notion that diagnosis at an early age suggests a more severe 
form of the disorder but perhaps instead a milder variant, as suggested by the modestly 
significant and negative relationship between IQ and ratings of illness severity. In addition 
to the potential artifacts noted above (e.g., a verbal individual may influence positive ratings 
even when showing heightened illness severity), this finding will require replication and 
elucidation in the context of the potential effects of duration of untreated psychosis (i.e., it is 
possible that illness onset at a younger age increases the likelihood of early detection and 
treatment, shortening the duration of untreated psychosis and attenuating progressive 
pathological processes) or youth at imminent risk for violence or suicide—variables that 
were not measured in TEOSS. Further, the range of ages of onset in our study was restricted 
by the inclusion criteria (i.e., all of our subjects had an early-onset form of illness). Taken 
together, the generalizability of this finding to community-based samples may be lessened. 
In addition, although the use of illicit substances was not a factor for either of the clinical 
groups, these substances could have clear implications for the manifestation of psychotic 
illness and for gene–environment interactions in the onset of psychosis in later studies.51
Positive symptoms did not correlate with neurocognitive domain scores, which is consistent 
with studies of adults with first-episode and chronic SZ;45,52–54 but neither did negative 
symptoms. Across the adult studies that show a significant relationship between negative 
symptoms and cognitive dysfunction, the correlations typically are small in magnitude and 
account for a minor portion of the variance (often 10% to 15%).45,52–54 Even when the 
significant correlations of the neurocognitive domains with the CGI and adaptive behaviors 
obtained in this study are considered, the magnitude of these correlations accounted for only 
6% to 14% of the variance, similar to the range reported in adult studies.
Finally, from an assessment perspective, our sample seemed to tolerate the measures used in 
this study. The next step is to determine whether this battery is sensitive to cognitive 
changes following pharmacological intervention. Consistent with the design of the 
MATRICS Consensus Battery,44 our measures were selected to detect changes in 
neurocognitive functioning secondary to medication effects. In that regard, our measurement 
does map onto many of the domains contained within the MATRICS Battery, such as 
Attention/Vigilance, Working Memory, Reasoning/Problem Solving, and Social Cognition. 
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Our findings suggest that the selected tasks are appropriate for assessing the neurocognitive 
functioning in youth with EOSS. The associations between neurocognitive performance and 
adaptive behavior or global functioning reinforce the potential value of measuring 
neurocognition and, perhaps, regarding it as an important treatment target in its own right.
The primary purpose of this study was to examine the similarities and differences in 
neurocognitive performance in a well-characterized group of children and adolescents with 
SZ or SA. Our findings represent some of the first data examining this question in youth. 
We did not find any differences in the level of performance between the groups across the 
neurocognitive domains examined. For the larger sample, severity of illness is associated 
with greater neurocognitive and adaptive functioning deficits, but this is neither surprising 
nor diagnostically specific. The lack of a definitive neurocognitive profile unique to any 
given psychotic disorder is a predictable outcome given substantial clinical and etiological 
heterogeneity within derived diagnostic categories. Recent findings suggest that 
schizophrenia spectrum disorders are characterized by marked genetic heterogeneity.55–57 
These disorders appear to stem from a large number of different overlapping disruptions in 
key neurodevelopmental pathways. As these critical pathways are identified, neurocognitive 
research can focus on the impact of disruptions in specific brain networks, rather than on 
global findings shared across groups of individuals with phenotypically related but 
heterogeneous syndromes.58
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TABLE 1
Demographics Characteristics for the Total Sample and Clinical Subsamples
Characteristic Total Sample (N = 119) Schizophrenia (n = 79) Schizoaffective (n = 40)
Chronological age (y) 14.25 (2.41) 14.26 (2.45) 14.22 (2.38)
Gender (% male) 65.6% 63.3 70.0%
Race (% white) 61.4% 57.0% 70.0%
Family incomea* 2.75 (1.52) 2.55 (1.42) 3.17 (1.65)
Handedness (% Right) 88.3% 87.3% 90.0%
Special education (%) 45.0% 39.4% 55.9%
Number of previous psychiatric hospitals 0.73 (0.93) 0.64 (.87) .92 (1.01)
Prior medication use (%) 55.5% 51.9% 62.5%
Age at first psychosis 11.13 (3.48) 11.40 (3.29) 10.54 (3.85)
Duration of Illness (mo) 37.60 (30.09) 34.73 (27.69) 43.82 (34.33)
PANSS positive 26.46 (5.75) 26.63 (5.52) 26.11 (6.25)
PANSS negative* 25.17 (8.18) 26.35 (8.56) 22.71 (6.77)
PANSS summary 101.56 (20.23) 103.38 (20.70) 97.76 (19.09)
CGI 5.61 (0.87) 5.70 (0.88) 5.45 (0.82)
BPRS-C 42.96 (11.40) 42.98 (11.68) 42.92 (10.97)
Note: BPRS-C = Brief Psychiatric Rating Scale for Children; CGI = Clinical Global Impression Scale; PANSS = Positive and Negative Symptom 
Scale.
a
Family Income: 1 = 20,000; 2 = $20,000–$40,000; 3 = $40,000–$60,000; 4 = $60,000–$80,000; 5 = $80,000–$100,000; 6 > $100,000.
*p < .05.
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TABLE 3
Group Comparisons of Neurocognitive Variables, Controlling for Chronological Age
Domain Total N Schizophrenia Schizoaffective F Value
Fine Motor Speed 105 0.01 (0.82) −0.06 (0.82) .07
 Fingertapping–Dominant Hand 91 0.12 (1.02) −0.23 (.93) 2.36
 Fingertapping–Nondominant Hand 89 0.09 (1.04) −0.15 (.92) .97
 Grooved Pegboard–Dominant Hand 97 −0.00 (1.00) 0.01 (1.01) .05
 Grooved Pegboard–Nondominant Hand 97 −0.05 (1.01) 0.08 (1.00) .65
Attention 99 0.06 (0.88) −0.08 (0.86) .39
 Visual CPT Omissions 91 0.04 (0.89) −0.09 (1.21) .31
 Auditory CPT Omissions 89 0.03 (1.12) −0.05 (0.77) .004
Working Memory 106 −0.09 (0.84) 0.13 (0.74) 2.08
 WJ-III Numbers Reversed Total 93 −0.07 (1.04) 0.12 (0.92) 1.64
 Hopkins Verbal Learning Total 98 −0.02 (0.93) 0.03 (1.13) .14
 Visual-Spatial Working Memory (5′Delay) 81 −0.13 (1.17) 0.21 (0.61) 3.04†
 WRAML Visual Learning Total 96 −0.08 (0.95) 0.13 (1.08) .66
Problem Solving Efficiency 107 −0.04 (0.87) −0.04 (0.79) .03
 Wisconsin Card Sort Categories 90 −0.04 (1.02) 0.06 (0.97) .55
 Wisconsin Card Sort Perseverations 90 −0.01 (0.93) 0.01 (1.12) .11
 Ruff Figural Fluency Unique Total 95 0.01 (1.05) −0.02 (0.93) .03
 COWA Semantic Fluency Total 98 0.06 (1.01) −0.10 (0.99) .47
Inhibitory Control 99 −0.00 (1.01) −0.03 (0.70) 0.003
 Visual CPT Commissions 91 0.03 (0.97) −0.06 (1.08) .14
 Auditory CPT Commissions 89 −0.01 (1.15) 0.02 (0.66) .10
Social Cognition/Eyes Test 94 0.04 (1.04) −0.06 (0.95) .17
Note: CPT = Continuous Performance Test; WJ-III = Woodcock-Johnson Test of Cognitive Abilities Third Edition; WRAML = Wide Range 
Assessment of Memory and Learning; COWA = Controlled Oral Word Association Test. All scores are reported in z-scores derived from the raw 
scores for the tests from the total sample. All scores have been scaled such that higher scores reflect a better performance.
†p < .10.
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TABLE 4
Partial Correlations Between the Neurocognitive Domains and Vineland Adaptive Behavior Scale
Neurocognitive Domains Communication Daily Living Skills Social Adaptive Composite
Fine-Motor Speed 0.16 0.22* 0.24** 0.25**
Attention 0.37*** 0.41*** 0.33*** 0.42***
Working Memory 0.45*** 0.28** 0.42*** 0.44***
Problem Solving Efficiency 0.40*** 0.26** 0.44*** 0.41***
Inhibitory Control 0.23* 0.12 0.14 0.19§
Social Cognition 0.21* 0.17 0.27** 0.23*
Full-4 IQ 0.39*** 0.22* 0.38*** 0.39***
*p < .05;
**p < .01;
***p < .001;
§p < .07.
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